Zobrazeno 1 - 10
of 17
pro vyhledávání: '"63"'
Publikováno v:
Gastroenterology. 148:S-89
Introduction Efforts have been focused on the prevention of overt upper gastrointestinal bleeding (UGIB), using acid inhibitors, particularly in users of NSAIDs and anti-thrombotic therapy (ATT). Little is known about the impact of such efforts on oc
Autor:
Antonio E. Cunha, Joao V. Rodrigues, Nghiep Truong Tan, Mathieu Cinier, Robert Gurny, Christel Rousseaux, Olivier Kitten, Leonardo Scapozza, Magali Zeisser Labouebe
Publikováno v:
Gastroenterology. 148:S-685
Background: Although worldwide data has clearly shown the persistent rise in paediatric inflammatory bowel disease (PIBD), trends in the incidence of early-onset PIBD (i.e. diagnosed before their 10th birthday; Paris A1a) are not yet clear. Recent ad
Autor:
Jessica Y.L. Ching, Nelson N.S. Kung, Yiu W. Luk, Ka F. To, Francis K.L. Chan, Joseph J.Y. Sung, Michael K.W. Li, Justin C.Y. Wu, S.C.Sydney Chung, James Y.W. Lau, Wai K. Leung, Samuel P.Y. Kwok, Yuk Tong Lee
Publikováno v:
Gastroenterology. 124(3)
Background & Aims: Fecal occult blood testing (FOBT), flexible sigmoidoscopy (FS), and colonoscopy are the most commonly recommended screening tests for colorectal cancer. The aim of this study was to compare the accuracy and safety of these 3 screen
Publikováno v:
Gastroenterology. 146:S-317
Fundic gland polyps (FGPs) are the most common type of gastric polyp and are seen in up to 5% of patients on endoscopy. Although considered benign, FGPs are more common in patients with familial adenomatous polyposis (FAP). FGPs occur sporadically in
Autor:
Beatriz Benitez Garcia, Cristina De Diego, Dora Pascual Salcedo, José Manuel Suárez de Parga, María Dolores Martín Arranz, Joaquín Poza Cordón, Eduardo Arranz, Silvia Gómez Senent
Publikováno v:
Gastroenterology. 146:S-243
Background: Adalimumab (ADA), a monoclonal antibody against TNFα is effective therapy for inflammatory bowel diseases (IBD: ulcerative colitis (UC) and Crohn's disease (CD)). Loss of response to ADA may be the consequence of increased ADA clearance
Autor:
Revital Kariv, Erwin Santo, Iris Dotan, Lior Yahav, Henit Yanai, Merav Ben-Yehoyada, Sigal Fishman, Diane R. Mould, Yulia Ron
Publikováno v:
Gastroenterology. 146:S-243
Background: Adalimumab (ADA), a monoclonal antibody against TNFα is effective therapy for inflammatory bowel diseases (IBD: ulcerative colitis (UC) and Crohn's disease (CD)). Loss of response to ADA may be the consequence of increased ADA clearance
Autor:
Emmanuel C. Gorospe, Prasad G. Iyer, Lori S. Lutzke, Subhash Chandra, Kenneth K. Wang, Cadman L. Leggett
Publikováno v:
Gastroenterology. 144:S-685
Background: Barrett's esophagus (BE) is the strongest risk factor for and precursor of most esophageal adenocarcinomas (EAC). Recent data has emerged suggesting a lower risk of progression than previously estimated. This has important bearing on deci
Publikováno v:
Gastroenterology. 144:S-604
Introduction: Diabetes mellitus type II (DM), is associated with increased risk of colorectal neoplasia. Yet, it is unclear if diabetes impacts initiation of colorectal neoplasia in subjects younger than the recommended average risk screening age. Ai
Autor:
Alexander C. Ford, Rebecca M. Lovell
Publikováno v:
Gastroenterology. 142:S-400
Introduction It has always been assumed that irritable bowel syndrome (IBS) is more common in women. However, there has been no systematic review and meta-analysis that has synthesised data from all available studies to estimate prevalence of IBS acc
Publikováno v:
Gastroenterology. 142:S-775
Introduction Screening colonoscopy has not had a big impact in reducing right sided cancer mortality and it is believed that this could partly be due to sessile serrated lesions (SSLs) which are thought to be the precursors of microsatellite adenocar